Gland Pharma share price jumps 16% after Q4 FY26 results

Market reaction: Gland Pharma spikes to a fresh 52-week high

Gland Pharma shares saw strong buying interest in the first session of the week on Monday, May 18, after the company reported its Q4 and full-year results for FY26. The rally was supported by positive brokerage commentary that highlighted improving growth momentum and better profitability. On the BSE, the stock surged as much as 16.22 percent during the session to touch ₹2,170, marking a 52-week high. The move came even as broader markets were weak, underlining the defensive rotation that investors have shown towards pharmaceutical stocks.

Intraday prices versus a weak Sensex

After touching the day’s high, the stock pared some gains but remained firmly in the green. At 09:37 AM, Gland Pharma was trading at ₹2,095, up 12.21 percent from the previous close. During the same time window, the BSE Sensex was down 855 points, or 1.14 percent, at 74,382. The divergence between the stock and the benchmark index reinforced the view that stock-specific triggers and earnings delivery were driving the move.

Q4FY26 earnings: revenue up 22%, profitability improves

For Q4FY26, Gland Pharma reported revenue from operations of ₹1,742.8 crore, up 22 percent year-on-year from ₹1,424.9 crore in Q4FY25. The company’s adjusted profit after tax (APAT) nearly doubled to ₹366.7 crore from ₹186.5 crore, reflecting a 97 percent year-on-year increase. Separately, the article also cites a year-on-year net profit rise of 96.6 percent to ₹186.5 crore for the quarter ended March 31, 2026. EBITDA for the quarter was reported at ₹513 crore, up 48 percent year-on-year, with EBITDA margin improving to 29.4 percent.

Dividend announcement for FY26

Alongside the results, the board recommended a final dividend of ₹20 per equity share of face value ₹1 for FY26. The company described this as 2,000 percent, consistent with the face value cited. Dividend announcements often act as a near-term support for sentiment, particularly when they accompany stronger quarterly performance.

Elara Capital stays constructive, lifts target to ₹2,306

Elara Capital retained its Buy call on Gland Pharma and raised its target price to ₹2,306 from ₹2,225. The brokerage cited improving growth momentum, strong product launches, and margin expansion as key positives. Elara’s valuation framework was described as 25x FY28E core EPS plus cash per share, and it noted that Gland Pharma currently trades at 25x FY27E core P/E. Elara also pointed to management’s guidance of 12-13 percent constant-currency top-line growth in FY27, and said ex-Cenexi EBITDA margin guidance of 33-35 percent appeared conservative.

Motilal Oswal reiterates Buy, highlights earnings beats

Motilal Oswal Financial Services (MOFSL) reaffirmed its Buy rating and set a target price of ₹2,300. The brokerage said the company delivered better-than-expected performance, with an 8 percent, 25 percent, and 40 percent beat on revenue, EBITDA, and PAT for the quarter, marking the second consecutive earnings beat. MOFSL said it values the company at 27x 12-month forward earnings. It also flagged record core-market revenue, improving profitability at Cenexi, and potential growth opportunities from CDMO and GLP-1.

Cenexi profitability and guidance in focus

Brokerage commentary referenced improving Cenexi profitability and stated that Cenexi’s EBITDA remains positive despite a lower top-line quarter-on-quarter. Guidance and profitability improvement at overseas subsidiaries can materially influence consolidated margins and investor confidence. The broker notes also referenced currency depreciation tailwinds as one of the factors behind earnings estimate upgrades.

Stock snapshot and key levels mentioned

During Monday’s session, the stock’s move to ₹2,170 implied a market capitalization of a little more than ₹35,000 crore. The article also provides separate reference points: as of May 15, 2026 at 15:50, Gland Pharma’s share price was ₹1,868.30, with a stated 52-week high of ₹2,131.00 and 52-week low of ₹1,452.20. Valuation metrics cited for the same timestamp were P/E of 30.00 and P/B of 3.22. The EPS numbers cited were 22.26 for the quarter ended March 2026 and 62.35 for FY2025-26.

Key numbers at a glance

Broker targets, ratings mix, and what investors track next

The article also cites Refinitiv-compiled analyst recommendations from 15 analysts: Buy 60 percent, Hold 13.33 percent, and Sell 26.67 percent. Beyond near-term price action, the immediate monitorables highlighted by broker notes include execution on product launches, the trajectory of Cenexi profitability, and progress on CDMO opportunities. Management’s guidance of 12-13 percent constant-currency top-line growth in FY27 and ex-Cenexi EBITDA margin guidance of 33-35 percent are likely to remain central reference points as investors track subsequent updates.